Navigation Links
Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
Date:11/5/2008

- Product Revenue Increased 78 Percent Compared with 2007 -

- Net Loss Narrows -

- Quantitative HER2 Scores Now Included in All Oncotype DX Reports -

- Conference Call Today at 4:30 p.m. ET -

REDWOOD CITY, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2008.

Total revenue increased to $28.1 million in the third quarter of 2008 compared with $15.9 million in the third quarter of 2007. Product revenue from the Oncotype DX(R) breast cancer assay was $28.1 million in the third quarter of 2008, an increase of 78 percent, compared with $15.8 million in the third quarter of 2007.

Net loss decreased to $3.0 million in the third quarter of 2008, compared with $7.3 million in the third quarter of 2007. Basic and diluted net loss per share was $0.11 in the third quarter of 2008, compared with a net loss per share of $0.26 in the third quarter of 2007.

Cash and cash equivalents and short-term investments at September 30, 2008 were $54.4 million compared with $60.6 million at June 30, 2008, and $68.4 million at December 31, 2007.

"We believe personalized medicine has the power to improve the quality of care while reducing costs, which is especially important during a time of soaring health care expenses and economic uncertainty," said Randy Scott, Ph.D., Chairman and Chief Executive Officer of Genomic Health. "This quarter, we again increased the value of Oncotype DX by the inclusion of quantitative HER2 scores, while continuing to invest in our commercial organization here and abroad. We believe the growing use of our Oncotype DX breast cancer assay, our narrowing net loss, and our strong balance sheet attest to the strength of our business model as we deliver the promise of genomics into the practice of medicine."

Additional Third Quarter 2008 Financial Results

The majority of product revenue, approximately 52 percent, was recorded on an accrual basis and recognized at the time the test results were delivered during the third quarter of 2008, reflecting established payment patterns from payors with coverage policies in place.

Total operating expenses were $31.4 million in the third quarter of 2008, compared with $24.0 million for the third quarter of 2007. Included in third quarter 2008 operating expenses were non-cash charges of $3.6 million, including $2.3 million of stock-based compensation expense, compared with $1.6 million in the same period in 2007, and $1.3 million of depreciation and amortization expenses, compared with $1.0 million in the same period in 2007.

Financial Results for Nine Months Ended September 30, 2008

Total revenue for the nine months ended September 30, 2008 was $79.3 million, compared with $44.7 million for the first nine months of 2007. Product revenue for the nine months ended September 30, 2008 was $77.8 million, compared with $43.5 million for the first nine months of 2007. Contract revenue constituted the balance of revenue for the first nine months of 2008 and 2007.

Net loss for the nine months ended September 30, 2008 was $13.8 million, compared with $21.3 million for the first nine months of 2007. Basic and diluted net loss per share was $0.49 for the nine months ended September 30, 2008, compared with a net loss per share of $0.81 for the first nine months of 2007.

Total operating expenses for the nine months ended September 30, 2008 were $94.2 million, compared with $67.6 million for the comparable period in 2007. The increase in expenses includes non-cash charges of $10.5 million, including stock-based compensation expense of $6.9 million in the first nine months of 2008 compared with $4.5 million for the same period in 2007, and $3.6 million of depreciation and amortization expenses, compared with $2.9 million in the same period in 2007.

Recent Highlights and Accomplishments

Commercial Progress

-- More than 10,220 test results delivered in the third quarter of 2008,

compared with more than 5,950 test results delivered in the third

quarter of 2007, an increase of 72 percent year-over-year.

-- More than 75,000 Oncotype DX test results have been delivered to

patients.

-- Gained coverage for an additional 7.9 million lives for reimbursement

of Oncotype DX through contracts, policies and agreements, bringing the

total U.S. covered lives to approximately 89 percent of insured lives

including: Coventry Health Care (4.4 million lives), Blue Cross and

Blue Shield of Massachusetts (1.3 million lives), Medica Health Plans,

HMSA Blue Cross Blue Shield of Hawaii, and WPS Health Insurance in

Wisconsin.

-- Named a Vice President to oversee European markets.

-- Established distribution agreements in Australia and Taiwan.

-- Received test samples from 39 countries to date.

-- Oncotype DX included in the updated 2008 guidelines of the Dutch

Institute for Healthcare Improvement.

Product Pipeline

-- Enhanced clinical utility of Oncotype DX reports by including

quantitative HER2 scores; quantitative estrogen receptor and

progesterone receptor scores were added earlier this year.

-- Completed European study using Oncotype DX in node-negative and

node-positive, breast cancer patients treated with aromatase

inhibitors, which was accepted for oral presentation at the San Antonio

Breast Cancer Symposium in December 2008.

-- Continued to make progress toward a clinical validation study in colon

cancer, with the goal of reporting results in 2009.

Peer-Reviewed Publications and Medical Meeting Presentations

-- Two abstracts were accepted for oral presentation at the San Antonio

Breast Cancer Symposium in December 2008:

-- "Risk of distant recurrence using Oncotype DX in postmenopausal

primary breast cancer patients treated with anastrozole or

tamoxifen: a TransATAC study"

-- "GRB7-dependent pathways are potential therapeutic targets in

triple-negative breast cancer"

-- The American Journal of Surgery published results of a study showing

Oncotype DX changed treatment recommendations in 44 percent of node-

negative, estrogen receptor-positive breast cancer patients.

-- Presented results from two studies supporting the use of Oncotype DX in

assessing HER2 gene expression at the ASCO Breast Cancer Symposium in

September.

-- Independent researchers presented results from a small study of

Japanese women demonstrating that the Oncotype DX Recurrence Score(R)

result may predict response to neoadjuvant endocrine therapy including

tamoxifen and anastrozole at the ASCO Breast Cancer Symposium in

September.

Conference Call Details

To access the live conference call today, November 5, at 4:30 p.m. Eastern Time via phone, please dial (877) 356-8064 from the United States and Canada or (706) 758-4314 internationally. The conference ID is 71000165. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 12 and may be accessed by dialing (800) 642-1687 from the United States and Canada or (706) 645-9291 internationally. The replay passcode is 71000165.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.genomichealth.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our beliefs regarding the ability of personalized medicine to improve the quality of healthcare while reducing costs; the components of future growth, if any, in our business; our belief that including quantitative HER2 scores increases the value of Oncotype DX; our beliefs regarding continued investment in our commercial organization domestically and abroad; our beliefs regarding the strengths of our business model; the outcome or success of planned or ongoing clinical trials and our expectations regarding potential clinical outcomes; and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our test; the risk that we may not obtain or maintain sufficient or increasing levels of reimbursement for our existing test and any future tests we may develop; our ability to continue to narrow our net loss; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to compete against third parties; our ability to develop and commercialize new tests; the results of clinical trials; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward- looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

Genomic Health, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

For the Three Months For the Nine Months

Ended September 30, Ended September 30,

2008 2007 2008 2007

(Unaudited) (Unaudited)

REVENUES:

Product revenues $28,070 $15,781 $77,752 $43,482

Contract revenues 51 120 1,592 1,197

Total revenues 28,121 15,901 79,344 44,679

OPERATING EXPENSES:

Cost of product revenues 7,140 4,398 19,875 12,417

Research and development 6,939 5,643 20,667 16,037

Selling and marketing 10,837 9,484 35,030 26,377

General and administrative 6,505 4,488 18,635 12,763

Total operating expenses 31,421 24,013 94,207 67,594

Loss from operations (3,300) (8,112) (14,863) (22,915)

Other income (expense):

Interest income 369 1,021 1,438 2,149

Interest and other expense (91) (162) (330) (535)

Net loss ($3,022) ($7,253) ($13,755) ($21,301)

Basic and diluted net

loss per share ($0.11) ($0.26) ($0.49) ($0.81)

Shares used in computing

basic and diluted net

loss per share 28,331,505 28,119,786 28,270,776 26,287,177

Genomic Health, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

September 30, December 31,

2008 2007

(Unaudited) (Audited)

Cash and cash equivalents $9,459 $39,164

Short-term investments 44,965 29,196

Accounts receivable, net 9,423 5,089

Prepaid expenses and other current assets 6,013 3,105

Total current assets 69,860 76,554

Property and equipment, net 14,583 10,412

Restricted cash 504 500

Other assets 564 463

Total assets $85,511 $87,929

Accounts payable $1,448 $1,966

Accrued expenses and other current liabilities 9,947 7,616

Deferred revenue 4,117 1,008

Notes payable, current 2,163 2,687

Notes payable, long-term 531 2,039

Other liabilities 1,814 1,447

Stockholders' equity 65,491 71,166

Total liabilities and stockholders' equity $85,511 $87,929

The condensed consolidated balance sheet at December 31, 2007 has been

derived from the audited consolidated financial statements at that date

included in the Company's Form 10-K for the fiscal year ended

December 31, 2007.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Florida , February 11, 2016 ... and Promote Genetic Understanding to Support Research and Discovery ... GenomeAsia 100K, today announced an ambitious plan to sequence 100,000 ... South Asian countries and at least 7 of North and ... In the first phase, the project will focus on ...
(Date:2/11/2016)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical solutions ... of the Steering Committee for its Pelvic Mass Registry. ... Pelvic masses can present physicians and healthcare professionals with ... ruled out, pelvic masses may include cancers of the ... tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit organization ... researched, developed, marketed and made accessible to patients around the ... had named the publication of the Good Pharma ... publication is also featured as one of BMJ Open ... last year that are most frequently read. Ed ...
(Date:2/11/2016)...  Wellcentive today announced it has been selected ... -based community care organization (CCO) with more than ... reporting and care management solutions and services. Wellcentive,s ... quality managers, analysts and care managers while providing ... FamilyCare members. Oregon ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):